Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

LON/AZN stock hub

LON/AZN has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/AZNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

207B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/AZN

In the news

Latest news · LON/AZN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E17.1

P25 12.9P50 16.9P75 23.5

Trailing P/E26.5

P25 15.9P50 22.9P75 35.8

ROE23.5

P25 -54.2P50 2.1P75 13.7

ROIC16.4

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/AZN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

247

Groups with data

Currency

USD

Showing 247 of 247 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	UK
Employees	96,100
Employees Change	1,800%
Employees Change Percent	1.91
Enterprise value	GBX 227B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	GB0009895292
Last refreshed	2026-05-10
Market cap	GBX 207B
Price	GBX 13,344
Price currency	GBX
Rev Per Employee	476,282.59x
Sector	Healthcare
Sic	2834
Symbol	lon/AZN
Website	https://www.astrazeneca.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.8%
EV Earnings	28.85x
EV/EBIT	20.1x
EV/EBITDA	14.7x
EV/FCF	26.54x
EV/Sales	4.96x
FCF yield	4.13%
Forward P/E	17.13x
P/B ratio	5.77x
P/E ratio	26.54x
P/S ratio	4.52x
PE Ratio10 Y	84.81x
PE Ratio3 Y	31.68x
PE Ratio5 Y	131.57x
PEG ratio	1.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.69%
EBITDA Margin	33.08%
FCF margin	18.68%
Gross margin	81.51%
Gross Profit	GBX 37.3B
Gross Profit Growth	8.69%
Gross Profit Growth Q	11.17%
Gross Profit Growth3 Y	10.18%
Gross Profit Growth5 Y	17.61%
Net Income	GBX 7.9B
Net Income Growth	33.67%
Net Income Growth Q	5.62%
Net Income Growth Quarters	10%
Net Income Growth Years	4%
Net Income Growth3 Y	30.22%
Net Income Growth5 Y	21.17%
Pretax Margin	21.37%
Profit Margin	17.19%
Profit Per Employee	GBX 81,869
Profitable Years	36
ROA	8.47
Roa5y	5.95
ROCE	18.32
ROE	23.48
Roe5y	13.03
ROIC	16.4
Roic5y	13.29

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	16.7%
Cagr15y	14.28%
Cagr1y	29.27%
Cagr20y	12.08%
Cagr3y	5.92%
Cagr5y	13.9%
Div CAGR10	2.28%
Div CAGR3	-0.42%
Div CAGR5	2.67%
EPS Growth	33.61
EPS Growth Q	5.35
EPS Growth Quarters	10
EPS Growth Years	4
EPS Growth3 Y	30.03
EPS Growth5 Y	16.98
FCF Growth	1.26%
FCF Growth Q	-14.37%
FCF Growth3 Y	9.55%
FCF Growth5 Y	15.06%
OCF Growth	8.66%
OCF Growth Q	-9.53%
OCF Growth10 Y	11.98%
OCF Growth3 Y	13.57%
OCF Growth5 Y	16.62%
Revenue Growth	9.93x
Revenue Growth Q	12.51x
Revenue Growth Quarters	12x
Revenue Growth Years	7x
Revenue Growth3 Y	11.3x
Revenue Growth5 Y	16.99x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	GBX 0.55
Assets	GBX 86.3B
Cash	GBX 5.8B
Current Assets	GBX 21.7B
Current Liabilities	GBX 23.9B
Debt	GBX 25.8B
Debt EBITDA	GBX 1.67
Debt Equity	GBX 0.72
Debt FCF	GBX 3.01
Equity	GBX 35.9B
Interest Coverage	10.59
Liabilities	GBX 50.5B
Long Term Assets	GBX 64.6B
Long Term Liabilities	GBX 26.6B
Net Cash	GBX -20B
Net Cash By Market Cap	GBX -9.64
Net Debt EBITDA	GBX 1.32
Net Debt Equity	GBX 0.56
Net Debt FCF	GBX 2.33
Tangible Book Value	GBX -8.2B
Tangible Book Value Per Share	GBX -5.26
WACC	5.24

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.91
Inventory Turnover	1.8
Net Working Capital	GBX -1.9B
Quick ratio	0.7
Working Capital	GBX -2.2B
Working Capital Turnover	GBX -15.39

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.08%
Dividend Growth	-3.83%
Dividend Growth Years	1%
Dividend per share	GBX 2.36
Dividend Years	34
Dividend Yield	1.77%
Ex Div Date	2026-02-19
Last Dividend	GBX 1.6
Payout Frequency	Semi-Annual
Payout Ratio	46.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	368.38%
1Y total return	29.25%
200-day SMA	13,300.8
3Y total return	18.83%
50-day SMA	14,473.4
50-day SMA vs 200-day SMA	50over200
5Y total return	91.7%
All Time High	15,732
All Time High Change	-15.18%
All Time High Date	2026-02-18
All Time Low	595
All Time Low Change	2,142.69%
All Time Low Date	1993-07-21
ATR	332.6
Beta	0.22
Beta1y	0.85
Beta2y	0.59
Ch YTD	-3.23
High	13,466
High52	15,732
High52 Date	2026-02-18
High52ch	-15.18%
Low	13,188
Low52	9,651
Low52 Date	2025-05-12
Low52ch	38.27%
Ma50ch	-7.8%
Price vs 200-day SMA	0.32%
RSI	34.49
RSI Monthly	55.41
RSI Weekly	46.1
Sharpe ratio	1.1x
Sortino ratio	2.24
Total Return	1.85%
Tr YTD	-2.23
Tr15y	640.44%
Tr1m	-10.79%
Tr1w	-1.24%
Tr3m	-4.41%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	GBX 11.3B
Operating Income Growth	10.65
Operating Income Growth Q	17.2
Operating Income Growth3 Y	14.17
Operating Income Growth5 Y	29.99
Operating margin	24.69

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,543,451,508%
Net Borrowing	874,348,688
Shares Insiders	0.04%
Shares Institutions	68.53%
Shares Out	1,550,988,781
Shares Qo Q	-0.13%
Shares Yo Y	-0.08%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	GBX 8.3B
Average Volume	1,782,453.45x
Bv Per Share	23.14
CAPEX	GBX -2.2B
Ch10y	251.3
Ch15y	331.3
Ch1m	-10.79
Ch1w	-1.24
Ch1y	27.04
Ch20y	355.4
Ch3m	-5.39
Ch3y	11.93
Ch5y	72.52
Ch6m	3.44
Change	0.23%
Change From Open	0.01
Close	13,314
Days Gap	0.21
Depreciation Amortization	3,718,915,980
Dollar Volume	32,797,163,424
Earnings Date	2026-04-29
EBIT	GBX 11.3B
EBITDA	GBX 15.1B
EPS	GBX 5.03
F Score	7
FCF	GBX 8.6B
FCF EV Yield	3.77x
FCF Per Share	GBX 5.51
Financing CF	-3,460,883,850
Fiscal Year End	December
Founded	1,992
Goodwill	15,546,095,716
Graham Number	5138.734
Graham Upside	-61.49
Income Tax	GBX 1.9B
Investing CF	-5,563,919,835
Is Primary Listing	1
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	GBX 10,740
Lynch Upside	-19.51
Ma150	13,893.7
Ma150ch	-3.96%
Ma20	14,247.8
Ma20ch	-6.34%
Net CF	1,747,102,635
Next Earnings Date	2026-07-27
Open	13,342
P FCF Ratio	24.2
P OCF Ratio	19.22
Payment Date	2026-03-23
Position In Range	56.12
Ppne	10,959,432,674
Price Date	2026-05-08
Price EBITDA	GBX 13.67
Relative Volume	1.38x
Revenue	45,770,756,895x
SBC By Revenue	0.61x
Share Based Comp	277,173,630
Tax By Revenue	4.17x
Tax Rate	19.52%
Tr20y	878.64%
Tr6m	4.51%
Volume	2,457,821
Z Score	3.35

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

LON/AZN dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.8%

$2.36 annual per share

Payout ratio

+46.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+2.7%

1 consecutive years of growth

Total shareholder yield

+1.9%

Next ex-dividend date: 2026-02-19

Performance

LON/AZN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/AZN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+68.5%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.1%

Negative means the company is buying back shares.

Technical

LON/AZN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

34.5

Neutral momentum band

Price vs 200-day MA

+0.3%

50/200-day relationship not available

Beta (5Y)

0.22

Less volatile than the market

Sharpe ratio

1.10

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/AZN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/AZN stock rating?

lon/AZN is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/AZN analysis?

The full report lives at /stocks/lon/AZN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/AZN?

The latest report frames lon/AZN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/AZN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.